High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao(Novartis Foundation), Joshua M. Korn(Novartis Foundation), Stéphane Ferretti(Novartis Foundation), John E. Monahan(Novartis Foundation), Youzhen Wang(Novartis (China)), Mallika Singh(Novartis Foundation), Chao Zhang(BioMarin (United States)), Christian Schnell(Novartis Institutes for BioMedical Research), Guizhi Yang(Novartis Foundation), Yun Zhang(Novartis Foundation), O. Alejandro Balbin(Novartis Foundation), Stéphanie Barbé(Novartis Institutes for BioMedical Research), Hongbo Cai(Novartis Foundation), Fergal Casey(Novartis Foundation), Susmita Chatterjee(Novartis Foundation), Derek Y. Chiang(Novartis Foundation), Shannon Chuai(Novartis (China)), Shawn Cogan(Novartis Foundation), Scott D. Collins(Novartis Foundation), Ernesta Dammassa(Novartis Institutes for BioMedical Research), Nicolas Ebel(Novartis Institutes for BioMedical Research), Millicent Embry(Novartis Foundation), John Green(Novartis Foundation), Audrey Kauffmann(Novartis Foundation), Colleen Kowal(Novartis Foundation), Rebecca Leary(Novartis Foundation), Joseph Lehár(Novartis Foundation), Ying Liang(Novartis Foundation), Alice Loo(Novartis Foundation), Edward Lorenzana(Novartis Foundation), E. Robert McDonald(Novartis Foundation), Margaret E. McLaughlin(Novartis Foundation), Jason J. Merkin(Novartis Foundation), Ronald A. Meyer(Novartis Foundation), Tara L. Naylor(Novartis Foundation), Montesa Patawaran(Novartis Foundation), Anupama Reddy(BioMarin (United States)), Claudia Röelli(Novartis Institutes for BioMedical Research), David A. Ruddy(Novartis Foundation), Fernando Salangsang(Novartis Foundation), Francesca Santacroce(Novartis Institutes for BioMedical Research), Angad Singh(Novartis Foundation), Yan Tang(Novartis Foundation), Walter Tinetto(Novartis (Switzerland)), Sonja Tobler(Novartis Institutes for BioMedical Research), Roberto Velazquez(Novartis Foundation), K. Venkatesan(Novartis Foundation), Fabian Von Arx(Novartis Foundation), Hui Qin Wang(Novartis Foundation), Zongyao Wang(Novartis Foundation), Marion Wiesmann(Novartis (Switzerland)), Daniel F. Wyss(Novartis (Switzerland)), Fiona Xu(Novartis (China)), Hans Bitter(Novartis Foundation), Peter Atadja(Novartis (China)), Emma Lees(Novartis Foundation), Francesco Hofmann(Novartis Foundation), En Li(Novartis Foundation), Nicholas Keen(Novartis Foundation), Robert Cozens(Novartis (Switzerland)), Michael Rugaard Jensen(Novartis (Switzerland)), Nancy Pryer(Novartis Foundation), Juliet Williams(Novartis Foundation), William R. Sellers(Novartis Foundation)
Cited by 1,431
Abstract
Related Papers
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al.|New England Journal of Medicine|2014|2.6k